Reagent composition for detecting beta-lactamase, detection kit and detection method

Abstract

It is intended to provide a reagent composition for detecting beta-lactamase which contains 3-[2,4-dinitrostyryl]-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid or 7-[2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-(2,4-dinitrostyryl)-3-cephem-4-carboxylic acid as a substrate for detecting beta-lactamase together with at least one beta-lactamase inhibitor selected from among clavulanic acid, aztreonam, ethylenediaminetetraacetic acid and cloxacillin and by which beta-lactamase can be quickly and easily identified at a high sensitivity. Moreover, a detection kit containing the above detection reagent composition and a method of detecting beta-lactamase comprising contacting a liquid specimen containing the subject to be analyzed with the above composition are provided.

Description

technical field [0001] The invention relates to a beta-lactamase detection reagent composition, a beta-lactamase detection kit and a beta-lactamase detection method. Background technique [0002] β-lactamases are a group of enzymes that hydrolyze the intramolecular β-lactam ring of β-lactam antibacterial agents, and are divided into A, B, C and D according to the homology of the amino acid sequence of the enzyme protein. Extended-spectrum β-lactamase (ESBL) is an enzyme that decomposes a wider range of substrates (β-lactam antibacterials) than conventional A-type β-lactamases. These β-lactamases inactivate the antibacterial activity of β-lactam antibacterial agents, and among them, ESBL has been regarded as a problem as a pathogen of nosocomial infections. Even if a β-lactam antibacterial agent is administered to bacteria showing resistance to the β-lactam antibacterial agent, not only the therapeutic effect cannot be obtained, but it may even cause the spread of new resist...

AI Technical Summary

Problems solved by technology

However, this international publication pamphlet does not disclose the combination with a specific β-lactamase inhibitor, nor does it suggest the possibility of detecting other types of β-lactamases other than ESBL.

Images